1202 Hay Street
Level 5
West Perth, WA 6005
Australia
61 8 6305 0705
https://auscann.com.au
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Christopher Mews A.C.I.S., B. Bus, C.P.A. | Chief Financial Officer | 122,75k | N/A | N/A |
Ms. Rachel Jelleff Kerr | Company Secretary | N/A | N/A | N/A |
AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.
AusCann Group Holdings Ltds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.